An ad hoc committee will plan and conduct two public workshops whose agendas will identify and examine ongoing activities to implement the recommendations put forth in the IOM consensus report, A National Cancer Clinical Trials System for the 21st Century. The first workshop (to be held in early 2011) would invite all stakeholders charged with making changes to the system (e.g., National Cancer Institute (NCI), Food and Drug Administration (FDA), Office for Human Research Protections (OHRP), Centers for Medicare and Medicaid Services (CMS), NCI Cooperative Group Chairs, drug/biotech/device industry, patient advocates, investigators at academic and community sites, and private payers) to discuss what changes they plan to implement in response to the IOM recommendations. The second workshop (to be held in 2013) would reconvene the stakeholders to discuss progress made to date and to identify additional actions to take. Individually-authored summaries of the workshops will subsequently be prepared by a designated rapporteur.